Session » Abstracts: Vasculitis – ANCA-Associated II

Date: Tuesday, November 14, 2023

Time: 2:00PM-3:30PM

Meeting: ACR Convergence 2023

Abstract Number: 2491

Alignment Between the Novel 2022 ACR/EULAR Classification Criteria for ANCA-associated Vasculitis (AAV), Clinical Diagnosis and Organ Manifestations in a European AAV Cohort

Abstract Number: 2492

The Impact of Neurologic Involvement in ANCA-Associated Vasculitis on Self-Reported Health-Related Quality of Life

Abstract Number: 2493

Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis

Abstract Number: 2494

Complement mRNA Expression in Patients with ANCA-associated Glomerulonephritis

Abstract Number: 2495

Unbiased Proteomic Approach to Identify Novel Biomarkers of Disease Activity in ANCA- Associated Vasculitis

Abstract Number: 2496

HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.